Skandinaviska Enskilda Banken AB publ Buys 193,918 Shares of Hologic, Inc. (NASDAQ:HOLX)

Skandinaviska Enskilda Banken AB publ boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 109.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 370,623 shares of the medical equipment provider’s stock after purchasing an additional 193,918 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Hologic were worth $27,519,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Jump Financial LLC purchased a new stake in Hologic during the fourth quarter valued at approximately $419,000. PNC Financial Services Group Inc. lifted its holdings in shares of Hologic by 0.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 31,933 shares of the medical equipment provider’s stock valued at $2,282,000 after purchasing an additional 288 shares during the last quarter. Coldstream Capital Management Inc. acquired a new stake in shares of Hologic in the 4th quarter worth $305,000. D.A. Davidson & CO. purchased a new position in Hologic during the 4th quarter worth $204,000. Finally, Corient Private Wealth LLC increased its position in Hologic by 251.1% during the 4th quarter. Corient Private Wealth LLC now owns 51,106 shares of the medical equipment provider’s stock valued at $3,652,000 after buying an additional 36,550 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on HOLX shares. Evercore ISI raised their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday. Royal Bank of Canada reissued a “sector perform” rating and set a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. Stephens reaffirmed an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Finally, StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Hologic Price Performance

NASDAQ:HOLX opened at $81.39 on Friday. The firm’s fifty day moving average is $80.74 and its two-hundred day moving average is $77.05. The firm has a market cap of $18.99 billion, a price-to-earnings ratio of 41.53, a PEG ratio of 2.53 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.93 earnings per share. Research analysts expect that Hologic, Inc. will post 4.09 EPS for the current year.

Insiders Place Their Bets

In other news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the transaction, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now owns 45,472 shares in the company, valued at $3,615,024. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,280 shares of company stock worth $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.